R14
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 48
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- COAGULATION+0.240
- MYOGENESIS+0.230
- E2F_TARGETS+0.210
- IL2_STAT5_SIGNALING+0.190
- APICAL_JUNCTION+0.170
- APICAL_SURFACE+0.170
- KRAS_SIGNALING_DN+0.160
- PANCREAS_BETA_CELLS+0.160
Top 10 suppressed
- PROTEIN_SECRETION-0.350
- OXIDATIVE_PHOSPHORYLATION-0.300
- ANDROGEN_RESPONSE-0.290
- PI3K_AKT_MTOR_SIGNALING-0.280
- MYC_TARGETS_V1-0.270
- MYC_TARGETS_V2-0.250
- TGF_BETA_SIGNALING-0.250
- TNFA_SIGNALING_VIA_NFKB-0.240
- ADIPOGENESIS-0.220
- HYPOXIA-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R396 | — | — | 0.854 |
| 2 | MDT-AP-0317 | Med | Medulloblastoma | 0.769 |
| 3 | GSM5359446 | — | — | 0.769 |
| 4 | SRR12202473 | — | — | 0.769 |
| 5 | R402 | — | — | 0.762 |
| 6 | R426 | — | — | 0.736 |
| 7 | BS_JT82QGXF | Med | Medulloblastoma | 0.723 |
| 8 | SRR819793 | GTEX | — | 0.720 |
| 9 | MDT-AP-0374 | Med | Medulloblastoma | 0.720 |
| 10 | MNG1166 | — | — | 0.720 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |